Articles

The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors

Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
Center for Biostatistics, The Ohio State University, Columbus, OH, USA
Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA;Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA
Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA
Stemline Therapeutics, Inc., New York, NY, USA
Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA;Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA
Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA;Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA
Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA;Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA
Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA;Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA
Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA;Department of Pathology, College of Medicine, The Ohio State University, Columbus, OH, USA
Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA;Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA
Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA;Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA
Vol. 103 No. 8 (2018): August, 2018 https://doi.org/10.3324/haematol.2018.188193